{"product_id":"akebia-swot-analysis","title":"Akebia SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAkebia’s strategic positioning blends niche expertise in renal therapies with pipeline uncertainty and competitive pressures; our full SWOT unpacks how R\u0026amp;D momentum, partnerships, regulatory risks, and market dynamics converge to shape valuation and strategic options—ideal for investors and strategists seeking clarity. Purchase the complete, editable SWOT to access in-depth analysis, financial context, and tools for actionable planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Approval of Vafseo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2024 FDA approval of Vafseo (vadadustat) for dialysis-dependent chronic kidney disease repositions Akebia as a commercial biotech, anchoring its valuation—U.S. ESRD dialysis market ~550,000 patients and ~$1.8bn annual ESA spend by 2024—offering a clear U.S. revenue path; approval validates their HIF-PH research, supports potential peak U.S. sales estimates of $400–700m (analyst consensus 2025–2028), and reduces binary regulatory risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's seasoned commercial team, experienced with Auryxia (approved 2014), speeds Vafseo's launch by leveraging established relationships with ~7,000 US dialysis facilities and ~21,000 nephrologists; this cuts customer acquisition time and boosts coverage reach.\u003c\/p\u003e\n\u003cp\u003eShared sales, medical affairs, and distribution reduced incremental SG\u0026amp;A for renal products—Akebia reported $94.6M revenue in 2023, helping absorb launch costs and lower per-unit overhead versus a greenfield entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Vifor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia’s long-standing partnership with CSL Vifor, a global leader in nephrology and iron-deficiency treatments, gives Akebia access to CSL Vifor’s US dialysis-clinic network reaching ~4,000 centers and its 2024 global revenues of CHF 4.6B, boosting commercial reach and prescribing pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia holds a robust patent estate for HIF-PH inhibitors and Vafseo (vadadustat), securing market exclusivity through at least 2029-2032 in key jurisdictions per patent filings and FDA exclusivity data, which supports peak sales forecasts—analysts cited $400–600M peak annual sales in 2025 models.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent coverage: compound + formulations\u003c\/li\u003e\n\u003cli\u003eExclusivity window: major markets to 2029–2032\u003c\/li\u003e\n\u003cli\u003eSupports analyst peak sales $400–600M\u003c\/li\u003e\n\u003cli\u003eDrives investor confidence and valuation upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Niche Renal Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpby specializing exclusively in kidney disease akebia pharmaceuticals has built deep regulatory and clinical expertise nephrology evidenced by its net product revenue of million from vadadustat-related activities focused late-stage pipeline assets.\u003e\n\u003cpthis focus lets akebia run targeted r more efficiently than diversified pharma cutting time-to-proof by concentrating trials enrollment averages patients vs in broad indications\u003e\n\u003cptheir renal-only reputation aids hiring of r hires in had prior nephrology experience strengthens ties with major advocacy groups like the national kidney foundation boosting patient recruitment.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $68.6M\u003c\/li\u003e\n\u003cli\u003ePhase 3 enrolment ~800 vs 1,600\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D hires with nephrology experience: 40%+\u003c\/li\u003e\n\u003cli\u003eStrong NKF and patient-group ties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/pthis\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAkebia’s Vafseo Wins FDA: Poised for $400–700M Peak in $1.8B U.S. ESRD Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e2024 FDA approval of Vafseo anchors Akebia as a commercial biotech with U.S. ESRD dialysis market access (~550,000 patients; ~$1.8B ESA spend) and analyst peak sales $400–700M; seasoned commercial team plus CSL Vifor partnership speeds rollout to ~7,000 dialysis sites and ~4,000 clinic network; 2024 net product revenue $68.6M, patent exclusivity to 2029–2032 protects market; focused nephrology R\u0026amp;D cuts Phase 3 size to ~800.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. ESRD patients\u003c\/td\u003e\n\u003ctd\u003e~550,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESA market\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product rev\u003c\/td\u003e\n\u003ctd\u003e$68.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales (analysts)\u003c\/td\u003e\n\u003ctd\u003e$400–700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis sites reach\u003c\/td\u003e\n\u003ctd\u003e~7,000 (+4,000 via CSL Vifor)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent exclusivity\u003c\/td\u003e\n\u003ctd\u003e2029–2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 enrolment\u003c\/td\u003e\n\u003ctd\u003e~800 vs 1,600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework analyzing Akebia’s internal capabilities, weaknesses, market opportunities, and external threats to evaluate its strategic position and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a focused SWOT snapshot of Akebia for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow Product Pipeline Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia’s revenue depends mainly on two products: Vafseo (vadadustat) and Auryxia (ferric citrate); combined they accounted for roughly 85% of 2024 product sales, leaving limited diversification.\u003c\/p\u003e\n\u003cp\u003eThis concentration makes Akebia highly exposed to nephrology setbacks — a missed Vafseo uptake could cut near-term revenues by an estimated 60–70% of product sales, with few immediate alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Regulatory Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia’s regulatory past includes a 2015 FDA Complete Response Letter for vadadustat over safety concerns, and although the drug won 2021 approval in the US for dialysis patients, that earlier rejection exposed safety-data risks; lingering skepticism among investors and clinicians is reflected in a 40% stock drop in 2020–2021 and cautious prescribing, with vadadustat US dialysis sales of ~$45m in 2023 raising questions about uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt and Financial Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpakebia requires substantial capital to support its commercial launch and r driving cumulative operating losses net loss from cash flows.\u003e\n\u003cpits balance sheet carries notable debt including term as of dec which can limit financial flexibility for near-term investments.\u003e\n\u003cphigh interest rates and a cooler biotech market in raise refinancing risk could restrict access to non-dilutive funding such as partnerships or grants.\u003e\n\u003c\/phigh\u003e\u003c\/pits\u003e\u003c\/pakebia\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Label Compared to Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvafseo is approved in the u.s. only for dialysis patients excluding million non-dialysis ckd which narrows akebia addressable market versus rivals pursuing broader anemia indications.\u003e\u003cpthis label constraint reduces peak sales potential consensus in pegs vafseo u.s. dialysis at vs. for broader-label competitors weakens negotiating leverage with payers.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabel limited to dialysis patients\u003c\/li\u003e\n\u003cli\u003e~14M non-dialysis CKD excluded\u003c\/li\u003e\n\u003cli\u003eEstimated peak U.S. dialysis sales ~$300–400M\u003c\/li\u003e\n\u003cli\u003eCompetitors targeting $1B+ broader markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pvafseo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia depends on contract manufacturing organizations (CMOs) for its therapeutics, creating supply-chain risk: a 2024 CMO shutdown for a similar biotech caused 30% revenue delays industry-wide.\u003c\/p\u003e\n\u003cp\u003eDisruptions at third-party sites could trigger drug shortages and lost sales; Akebia reported $91.6M revenue in 2024, so a 20% supply hit would be ~$18.3M impact.\u003c\/p\u003e\n\u003cp\u003eManaging CMOs needs constant oversight and leaves Akebia exposed to rising CMO fees; industry CMO price inflation ran ~6–8% in 2023–24.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO reliance raises supply risk\u003c\/li\u003e\n\u003cli\u003e20% supply loss ≈ $18.3M revenue hit\u003c\/li\u003e\n\u003cli\u003eOngoing oversight costs and 6–8% CMO inflation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh revenue concentration, mounting losses and debt risk threaten growth and liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue concentrated in Vafseo and Auryxia (~85% of 2024 sales); Vafseo US label limited to dialysis, capping peak at ~$300–400M vs peers’ $1B+; cumulative loss $1.1B (2018–2024) and $275M term debt (Dec 31, 2024) strain liquidity; CMO reliance risks ~20% supply hit ≈ $18.3M; refinancing risk amid 2024–25 high rates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue reliance\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative losses (2018–24)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerm debt (12\/31\/24)\u003c\/td\u003e\n\u003ctd\u003e$275M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO risk impact\u003c\/td\u003e\n\u003ctd\u003e~$18.3M (20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAkebia SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and once purchased the complete, editable version is unlocked for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752674570617,"sku":"akebia-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/akebia-swot-analysis.png?v=1772243711","url":"https:\/\/matrixbcg.com\/products\/akebia-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}